Johnson & Johnson reached a settlement deal with 36 states, ending a case alleging that it improperly marketed Risperdal and Invega for unapproved uses. The $181 million settlement is the largest agreement to come from a multistate consumer protection pharmaceutical case. Settlements like this demonstrate a lack of tolerance for marketing practices that risk dangerous medication or prescription errors.
For years doctors have prescribed a type of progesterone to pregnant women who were considered to be at high risk for premature delivery. Generally the cost of that medication was about $10 per dose and was made by specialty pharmacies.